Science & academia

Holding turmeric-like substance in front of Berkeley's Campanile

U.C. Berkeley researchers use turmeric-like powder to ‘clean the air entirely’ of carbon dioxide

/

New research from U.C. Berkeley, published in Nature, points to a new material – a bright yellow powder that resembles turmeric – that could help rid the air all around us of CO2. The scientists say that just 200 grams of the material can absorb up to 20 kilograms of carbon in a year – which is approximately the same absorption potential as a tree. The substance could be easily integrated into carbon capture systems already deployed to remove CO2 from refinery emissions or to capture atmospheric carbon and store it underground.

Blood cells under microscope

Danish scientists design new form of insulin that automatically switches itself on and off

/

For decades, researchers have been working to develop a system that can automatically adjust insulin activity based on the amount of glucose in a person’s blood. Now, Rita Slaaby, a principal scientist at pharmaceutical company Novo Nordisk in Bagsværd, Denmark, and her colleagues engineered an insulin molecule with a switch that turns its activity on and off in response to glucose levels in the blood. In animals, this ‘smart’ insulin reduces high blood-sugar concentrations effectively while preventing levels from dropping too low.

Insulin pens

New treatment eliminates insulin for 86% of patients in early trials

/

New research from Amsterdam University Medical Center introduces a promising new treatment approach for type 2 diabetes (T2D) that has the potential to greatly reduce or even eliminate the need for insulin therapy. This innovative approach, which combines a novel procedure known as ReCET (Re-Cellularization via Electroporation Therapy) with semaglutide, resulted in the elimination of insulin therapy for 86% of the 14 patients participating in initial trials. Globally, T2D affects 422 million people. While insulin therapy is commonly used to manage blood sugar levels in T2D patients, it can result in side effects such as weight gain and further complicate diabetes management.

Man clutching his chest from acute pain

New heart attack detector gives results in minutes, not hours

/

Someone presenting to the emergency room with a suspected heart attack will undergo a number of standard blood tests to determine heart muscle damage. The problem is that it can take one or two hours to receive the results. Now, Johns Hopkins University researchers have led the design of a tiny chip that diagnoses heart attack by detecting these important biomarkers in minutes rather than hours, even if they are present at very low concentrations. The researchers foresee an at-home heart attack detector in the future.

Ovarian and Cervical Cancer Awareness. a Teal Ribbon

New cervical cancer treatment regime ‘cuts risk of dying from disease by 40%’

/

Doctors are hailing a “remarkable” new treatment regime for cervical cancer developed by researchers at University College London that reduces the risk of dying by 40%, in the biggest advance against the disease in 25 years. The new treatment plan was tested in patients recruited over 10 years from the UK, Mexico, India, Italy, and Brazil. Cervical cancer is the fourth most common cancer in women globally, with about 660,000 new cases and 350,000 deaths every year, according to the World Health Organization.

Pollution from industrial facility

Study finds mercury pollution from human activities is declining

/

In a new study from the Massachusetts Institute of Technology, researchers analyzed measurements from all available monitoring stations in the Northern Hemisphere and found that atmospheric concentrations of mercury declined by about 10% between 2005 and 2020. They used two separate modeling methods to determine what is driving that trend. Both techniques pointed to a decline in mercury emissions from human activity as the most likely cause.

Scientists in the U.K. developing world’s first vaccine to prevent ovarian cancer

/

Researchers at the University of Oxford are working on the world’s first ovarian cancer vaccine, aiming to prevent the disease that kills nearly 26,000 women in the European Union every year. The vaccine, called OvarianVax, would train the immune system to recognize and fight back against the earliest stages of ovarian cancer, one of the most common forms of cancer among women which often isn’t detected until a later stage when it’s harder to treat. Cancer Research U.K. will fund the OvarianVax research with up to £600,000 for the effort.

Good news for scientific research

University of Toronto researchers develop method to accelerate forensic analysis in sexual assault cases

/

The entire process currently can take days, weeks, or longer. To speed things up, the researchers focused on the first step: separating two individuals’ DNA from a single sample. At present, this is usually done manually by trained and experienced experts. The new method uses a process called ’differential digestion” using digital microfluidics that helped simplify the overall process and reduce the number of manual steps needed to isolate the assailant’s DNA from 13 to five.

Depiction of embryonic stem cells in amniotic fluid

In world first, stem cells reverse woman’s diabetes

/

In the first trial of its kind, Deng Hongkui, a cell biologist at Peking University in Beijing, and his colleagues extracted cells from three people with type 1 diabetes and reverted them into a pluripotent state, from which they could be molded into any cell type in the body. Now, a 25-year-old woman with type 1 diabetes started producing her own insulin less than three months after receiving a transplant of reprogrammed stem cells. She is the first person with the disease to be treated using cells that were extracted from her own body.

Model lungs

World-first lung cancer vaccine trials launched across seven countries

/

Lung cancer is the world’s leading cause of cancer death, accounting for about 1.8 million deaths every year. Now experts are testing a new jab that instructs the body to hunt down and kill cancer cells – then prevents them from ever coming back. Known as BNT116 and made by BioNTech, the vaccine is designed to treat non-small cell lung cancer, the most common form of the disease. The phase 1 clinical trial, the first human study of BNT116, has launched across 34 research sites in seven countries: the U.K., U.S., Germany, Hungary, Poland, Spain, and Turkey.

Scroll to Top